Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.450
-0.100 (-3.92%)
Nov 4, 2024, 4:00 PM EST - Market closed

Moleculin Biotech Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2015
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2015
Net Income
-25.17-29.77-29.03-15.89-17.36-13.21
Upgrade
Depreciation & Amortization
0.130.130.130.160.20.2
Upgrade
Loss (Gain) From Sale of Assets
----0.01-0
Upgrade
Stock-Based Compensation
1.921.982.282.371.681.54
Upgrade
Other Operating Activities
-1.911.94-1.24-6.63-2.26-3.59
Upgrade
Change in Accounts Payable
-1.30.40.730.24-1.020.91
Upgrade
Change in Other Net Operating Assets
0.711.22-0.510.80.98-3.05
Upgrade
Operating Cash Flow
-25.62-24.1-27.64-18.95-17.77-17.2
Upgrade
Capital Expenditures
-0.12-0.12-0.07-0.02-0.38-0.05
Upgrade
Sale of Property, Plant & Equipment
----00
Upgrade
Investing Cash Flow
-0.12-0.12-0.07-0.02-0.37-0.05
Upgrade
Issuance of Common Stock
3.964.17-74.7522.5720.85
Upgrade
Repurchase of Common Stock
-0.03-0.03-0.02-0.02-0.02-
Upgrade
Other Financing Activities
0.510.51----
Upgrade
Financing Cash Flow
4.444.65-0.0274.7222.5520.85
Upgrade
Foreign Exchange Rate Adjustments
-0.02-0.02-0.03-0.020.03-0
Upgrade
Net Cash Flow
-21.33-19.6-27.7655.734.443.6
Upgrade
Free Cash Flow
-25.75-24.23-27.71-18.97-18.15-17.25
Upgrade
Free Cash Flow Per Share
-11.42-12.26-14.53-10.59-27.65-38.12
Upgrade
Cash Interest Paid
-----0
Upgrade
Cash Income Tax Paid
----0.020.02
Upgrade
Levered Free Cash Flow
-15.81-14.6-16.09-10.17-10.77-11.49
Upgrade
Unlevered Free Cash Flow
-15.81-14.6-16.09-10.17-10.77-11.49
Upgrade
Change in Net Working Capital
0.6-1.74-0.32-1.16-0.062.32
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.